Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The evolution of oral contraceptives. Maximizing efficacy, minimizing risks.

B Hedon1

  • 1Department of Obstetrics and Gynecology, Montpellier-Nimes University Hospital, France.

Acta Obstetricia Et Gynecologica Scandinavica. Supplement
|January 1, 1990
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of vulvovaginal atrophy: Physical therapies. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].

Gynecologie, obstetrique, fertilite & senologie·2021
Same author

[Normal childbirth: physiologic labor support and medical procedures. Guidelines of the French National Authority for Health (HAS) with the collaboration of the French College of Gynaecologists and Obstetricians (CNGOF) and the French College of Midwives (CNSF) - Method and organization].

Gynecologie, obstetrique, fertilite & senologie·2020
Same author

[Normal childbirth: physiologic labor support and medical procedures. Guidelines of the French National Authority for Health (HAS) with the collaboration of the French College of Gynaecologists and Obstetricians (CNGOF) and the French College of Midwives (CNSF) -- Text of the Guidelines (short text)].

Gynecologie, obstetrique, fertilite & senologie·2020
Same author

[Normal childbirth: physiologic labor support and medical procedures. Guidelines of the French National Authority for Health (HAS) with the collaboration of the French College of Gynaecologists and Obstetricians (CNGOF) and the French College of Midwives (CNSF) - Guidelines of the Haute Autorité de Santé - Introduction].

Gynecologie, obstetrique, fertilite & senologie·2020
Same author

[Contraception: CNGOF Guidelines for Clinical Practice (Short Version)].

Gynecologie, obstetrique, fertilite & senologie·2018
Same author

Guidelines for coordinated radiologist/gynecologist-obstetrician management of patients requiring fetal MRI or CT.

Diagnostic and interventional imaging·2017

Oral contraceptives (OCs) have evolved to be safer, with lower estrogen and progestin doses significantly reducing risks like thromboembolism and cardiovascular disease. Newer formulations focus on minimizing progestin

Area of Science:

  • Reproductive endocrinology and pharmacology.
  • Cardiovascular risk assessment in women's health.

Background:

  • Oral contraceptives (OCs) are the most studied reversible contraception.
  • Research focuses on maximizing OC benefits while minimizing risks like thromboembolic disorders and cardiovascular disease.

Observation:

  • Estrogen doses in OCs have decreased from 100-150 mcg to 30-50 mcg.
  • Progestin doses have also been reduced.
  • Androgenic activity of progestins may influence cardiovascular risk.

Findings:

  • Lower estrogen doses correlate with reduced risk of thromboembolic events.
  • Reduced progestin doses are linked to lower incidence of stroke and myocardial infarction.
  • The risk of thromboembolism is very small in healthy women.
Keywords:
BiologyCardiovascular EffectsContraceptionContraceptive Methods--beneficial effectsContraceptive Methods--historyContraceptive Methods--side effectsDiseasesEmbolismFamily PlanningHeart DiseasesLipid Metabolic EffectsLipidsMyocardial InfarctionOral Contraceptives--beneficial effectsOral Contraceptives--historyOral Contraceptives--side effectsPhysiologyThromboembolismVascular Diseases

Related Experiment Videos

Implications:

  • Development of OCs with low-dose estrogen and minimal androgenic progestins is advisable.
  • Current OCs offer a very small risk of thromboembolism for healthy women.
  • Further research into progestin's role in cardiovascular health is warranted.